UNSPSC 51322901: Clinofibrate

This classification denotes an anti-lipidemic agent with the molecular formula C28H36O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0374EZJ8CU, chemically known as 2,2-(cyclohexylidenebis(p-phenyleneoxy))bis(2-methylbutyric acid) but generally known as clinofibrate, which bears US NIH Compound Identifier 2787. European Medicines Agency schedules Clinofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06666MIG.

UNSPSC 51322901 Clinofibrate (Commodity) encompasses prescription and over-the-counter pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and employee health benefit plans. Recent solicitations under this code show state and local agencies purchasing specific medications through competitive sealed-bid processes, cooperative purchasing agreements, and direct-to-manufacturer initiatives. The City of Tampa's Fire Rescue division, for example, is actively procuring advanced life support medications including epinephrine, adenosine, labetalol, and diltiazem through sealed-bid IFB; Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is consolidating generic pharmaceutical and OTC product sourcing across multiple state and local member jurisdictions. Issuing bodies span municipal fire departments, state health agencies, and regional cooperative purchasing organizations that serve multiple states and local governments.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Advanced Life Support Medications IFB (26P00188) closed April 8, 2026, with an estimated contract value of $40,000 and a one-year initial term renewable for two additional years; the contract carries a 5 percent SLBE bid discount. The Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products closed March 26, 2026, with a two-year initial contract term and coverage extending to Oregon and other participating jurisdictions; vendors must distribute through AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson and comply with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements. Texas Health and Human Services Commission's Request for Information (HHS0017013) on direct-to-manufacturer prescription programs closed April 3, 2026, as a market-intelligence phase preceding formal RFP development. The code shows steady activity across municipal, state, and multi-state cooperative procurement channels.